Annual report 2022*
High-precision delivery
medmix designs, develops, manufactures and delivers innovative high-precision devices and services for the mixing, application and injection of liquids in a wide range of viscosities for the healthcare, consumer and industrial end-markets. On September 30, 2021, medmix spun off from Sulzer. Its shares have since been listed and traded on the SIX Swiss Exchange in Zurich (Securities no. 112.967.710/ISIN CH1129677105).
Read more about medmix here
* With amended chart in Corporate Governance, Board of Directors section
Letter to the shareholders
)
Our KEY Figures
477.1 m CHF
revenue in 2022
22.1 %
adjusted EBITDA margin
10.3 m CHF
free cash flow generated in 2022
The medmix strategy: platform for growth
)
The medmix approach to sustainability
)
